These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3513594)

  • 1. Glaucoma treatment with once-daily levobunolol.
    Wandel T; Charap AD; Lewis RA; Partamian L; Cobb S; Lue JC; Novack GD; Gaster R; Smith J; Duzman E
    Am J Ophthalmol; 1986 Mar; 101(3):298-304. PubMed ID: 3513594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once-daily levobunolol for glaucoma therapy.
    Rakofsky SI; Lazar M; Almog Y; LeBlanc RP; Mann C; Orr A; Lee PF; Friedland BR; Novack GD; Kelley EP
    Can J Ophthalmol; 1989 Feb; 24(1):2-6. PubMed ID: 2653592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of once-daily levobunolol 0.25% and timolol 0.25% therapy for increased intraocular pressure.
    Silverstone D; Zimmerman T; Choplin N; Mundorf T; Rose A; Stoecker J; Kelley E; Lue J
    Am J Ophthalmol; 1991 Jul; 112(1):56-60. PubMed ID: 1882923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical evaluation of the effects of topically applied levobunolol and timolol on increased intraocular pressure.
    Duzman E; Ober M; Scharrer A; Leopold IH
    Am J Ophthalmol; 1982 Sep; 94(3):318-27. PubMed ID: 6751091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levobunolol compared with timolol: a four-year study.
    Geyer O; Lazar M; Novack GD; Shen D; Eto CY
    Br J Ophthalmol; 1988 Dec; 72(12):892-6. PubMed ID: 3067745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of twice-daily levobunolol in the treatment of elevated intraocular pressure.
    Seamone C; LeBlanc R; Saheb N; Novack G
    Can J Ophthalmol; 1988 Jun; 23(4):168-70. PubMed ID: 3293726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD compared with 0.5% levobunolol hydrochloride BID in patients with open-angle glaucoma or ocular hypertension.
    Walters TR; Maloney S; Slater D; Liss C; Wilson H; Hartenbaum D
    Clin Ther; 1998; 20(6):1170-8. PubMed ID: 9916610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment.
    Rakofsky SI; Melamed S; Cohen JS; Slight JR; Spaeth G; Lewis RA; Zbrowski-Gutman L; Eto CY; Lue JC; Novack GD
    Ophthalmology; 1989 Jan; 96(1):8-11. PubMed ID: 2645553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pressure lowering effect and side effects of 0.5% and 1.0% levobunolol eyedrops, compared with 0.5% timolol eyedrops in patients with open-angle glaucoma].
    Stryz JR; Merté HJ
    Klin Monbl Augenheilkd; 1985 Dec; 187(6):537-44. PubMed ID: 3912600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the effectiveness and safety of levobunolol and timolol in ocular hypertension and chronic open-angle glaucoma].
    Freyler H; Novack GD; Menapace R; Skorpik C; Mordaunt J; Batoosingh AL
    Klin Monbl Augenheilkd; 1988 Sep; 193(3):257-60. PubMed ID: 3070134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cross-over trial comparing once daily levobunolol with once and twice daily timolol.
    Akafo SK; Thompson JR; Rosenthal AR
    Eur J Ophthalmol; 1995; 5(3):172-6. PubMed ID: 8845685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levobunolol. A beta-adrenoceptor antagonist effective in the long-term treatment of glaucoma. The Levobunolol Study Group (Appended).
    Ophthalmology; 1985 Sep; 92(9):1271-6. PubMed ID: 2865710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of levobunolol and dipivefrin for the treatment of glaucoma.
    Allen RC; Robin AL; Long D; Novack GD; Lue JC; Kaplan G
    Arch Ophthalmol; 1988 Jul; 106(7):904-7. PubMed ID: 3291837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levobunolol vs timolol for open-angle glaucoma and ocular hypertension.
    Cinotti A; Cinotti D; Grant W; Jacobs I; Galin M; Silverstone D; Shin D; Esters J; Lee J; Bouchey R
    Am J Ophthalmol; 1985 Jan; 99(1):11-7. PubMed ID: 3881032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levobunolol. A three-month efficacy study in the treatment of glaucoma and ocular hypertension.
    Bensinger RE; Keates EU; Gofman JD; Novack GD; Duzman E
    Arch Ophthalmol; 1985 Mar; 103(3):375-8. PubMed ID: 3883971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term evaluation of 0.25% levobunolol and timolol for therapy for elevated intraocular pressure.
    Boozman FW; Carriker R; Foerster R; Allen RC; Novack GD; Batoosingh AL
    Arch Ophthalmol; 1988 May; 106(5):614-8. PubMed ID: 3282501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levobunolol compared with timolol for the long-term control of elevated intraocular pressure.
    Berson FG; Cohen HB; Foerster RJ; Lass JH; Novack GD; Duzman E
    Arch Ophthalmol; 1985 Mar; 103(3):379-82. PubMed ID: 3883972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term ocular hypotensive effect of levobunolol: results of a one-year study.
    Ober M; Scharrer A; David R; Biedner BZ; Novack GD; Lue JC; Robins DS; Duzman E
    Br J Ophthalmol; 1985 Aug; 69(8):593-9. PubMed ID: 3893528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimum concentration of levobunolol required to control intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
    Long D; Zimmerman T; Spaeth G; Novack G; Burke PJ; Duzman E
    Am J Ophthalmol; 1985 Jan; 99(1):18-22. PubMed ID: 3881033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol.
    Behrens-Baumann W; Kimmich F; Walt JG; Lue J
    Ophthalmologica; 1994; 208(1):32-6. PubMed ID: 8145982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.